44859-7 |
Bacteria^^^7 |
Prid |
XXX |
Pt |
Nom |
Anaerobic culture |
|
ACTIVE |
Bacteria # 7 identified in Specimen by Anaerobe culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44859-7 |
|
Anaerobic culture |
|
|
Observation |
|
|
|
0 |
Bacteria Spec Anaerobe Cult org #7 |
|
|
|
N |
|
Anaero; Anaerobe; Anaerobe Cult; Bact; C&S; Cult; Cultures; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Nominal; Other; Point in time; Random; Spec; To be specified in another part of the message; Unspecified |
2.78 |
2.17 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
4486-7 |
Complement C3 fragment |
PrThr |
RBC |
Pt |
Ord |
|
|
ACTIVE |
Complement C3 fragment [Presence] in Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
4486-7 |
|
|
|
|
Both |
|
|
|
0 |
C3 Frg RBC Ql |
|
|
|
|
|
Beta 1 C-globulin; C3 Frg; Comp; Complmt; Erythrocytes; Frag; Fragments; HEMATOLOGY/CELL COUNTS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Red blood cells; Red blood corpusles; Screen |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44860-5 |
Methoxyacetate/Creatinine |
MRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Methoxyacetate/Creatinine [Mass Ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
44860-5 |
|
|
|
|
Both |
|
|
|
0 |
Methoxyacetate/Creat Ur |
|
|
|
N |
|
2-Methoxyacetic acid; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; MAA; Mass concentration ratio; Mass ratio; MCRto; Methoxyacetic acid; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.42 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
44861-3 |
4-Hydroxymandelate/Creatinine |
MRto |
Urine |
Pt |
Qn |
|
|
DISCOURAGED |
4-Hydroxymandelate/Creatinine [Mass Ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44861-3 |
|
|
|
|
Both |
|
|
|
0 |
4OHMandelate/Creat Ur |
|
|
|
N |
|
2-Hydroxy-2-(4-hydroxyphenyl)acetate; 4-Hydroxy mandelate; 4-hydroxymanelic acid; 4OHMandelate; Chemistry; CR; Crea; Creat; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.42 |
2.17 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
44862-1 |
5-Alpha tetrahydro-11-Dehydrocorticosterone/Creatinine |
MRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
5-Alpha tetrahydro-11-Dehydrocorticosterone/Creatinine [Mass Ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/g creatinine |
|
|
|
|
|
|
CHEM |
|
44862-1 |
|
|
|
|
Both |
|
|
|
0 |
5-A THB/Creat Ur |
|
|
|
N |
|
5-A THB; Alfa; Chemistry; CR; Crea; Creat; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; THA; UA; UCr; UR; Urn |
2.44 |
2.17 |
|
|
|
|
|
|
|
mg/g{creat} |
|
|
|
0 |
44863-9 |
6-Alpha hydroxytetrahydro-11-Dehydrocorticosterone/Creatinine |
MRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
6-alpha-hydroxytetrahydro-11-Dehydrocorticosterone/Creatinine [Mass Ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/g creatinine |
|
|
|
|
|
|
CHEM |
|
44863-9 |
|
|
|
|
Both |
|
|
|
0 |
6A-OH-THA/Creat Ur |
|
|
|
N |
|
6A-OH-THA; Alfa; Chemistry; CR; Crea; Creat; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.44 |
2.17 |
|
|
|
|
|
|
|
mg/g{creat} |
|
|
|
0 |
44864-7 |
6-Alpha hydroxytetrahydro-11-Deoxycortisol/Creatinine |
MRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
6-Alpha hydroxytetrahydro-11-Deoxycortisol/Creatinine [Mass Ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
mg/g creatinine |
|
|
|
|
|
|
CHEM |
|
44864-7 |
|
|
|
|
Both |
|
|
|
0 |
6A-OH-THS/Creat Ur |
|
|
|
N |
|
11DC; 6A-OH-THS; Alfa; Chemistry; Compound S; Cortexolone; Cortodoxone; CR; Crea; Creat; Deoxycortisol; Desoxycortisol; Mass concentration ratio; Mass ratio; MCRto; Metopirone; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.44 |
2.17 |
|
|
|
|
|
|
|
mg/g{creat} |
|
|
|
0 |
44865-4 |
Ammonium urate |
PrThr |
Calculus |
Pt |
Ord |
|
|
ACTIVE |
Ammonium urate [Presence] in Stone |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44865-4 |
|
|
|
|
Observation |
|
|
|
0 |
Amm Urate Stone Ql |
|
|
|
N |
|
Amm; Amm Urate; Ammon; Ammonium acid urate; Ammonium biurate; Calc; Calculi; Chemistry; NH4; NH4U; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Stn; Stone; Stones; UA; Urates; Uric acid |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44867-0 |
Iron.microscopic observation |
PrThr |
Body fld |
Pt |
Ord |
XXX stain |
|
ACTIVE |
Iron.microscopic observation [Presence] in Body fluid by Other stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATH |
|
44867-0 |
|
XXX stain |
|
|
Both |
|
|
|
0 |
Iron Fld Ql Other Stn |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Fe; Fl; Fld; FLU; Fluid; Ordinal; Other Stn; PATHOLOGY; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44868-8 |
Herpes simplex virus 1+2 DNA |
PrThr |
Vag |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Herpes simplex virus 1+2 DNA [Presence] in Vaginal fluid by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44868-8 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HSV1+2 DNA Vag Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Genital vaginal; Gyn; Gynecology; Herp splx; Herpes simplex virus type 1; Herpes simplex virus type 1+2; Herpes simplex virus type I+II; HSV; HSV 1+2; HSV1; HSV1+2; i; ID; II; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; OB; ObGyn; Obstetrics; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; Vag fld; Vag fluid; Vagina; Vaginal fluid |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44869-6 |
Histoplasma capsulatum Ab |
PrThr |
Ser |
Pt |
Ord |
CIE |
|
ACTIVE |
Histoplasma capsulatum Ab [Presence] in Serum by Counterimmunoelectrophoresis (CIE) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44869-6 |
|
CIE |
|
|
Both |
|
|
|
0 |
H capsul Ab Ser Ql CIE |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Counterimmunoelectrophoresis; H capsul; H capsulatum; H farciminosum; Histo; Histopl; Histoplasma farciminosum; Histoplasmos; Histoplasmosis; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
4487-5 |
Complement C3 fragment |
MCnc |
RBC |
Pt |
Qn |
|
|
ACTIVE |
Complement C3 fragment [Mass/volume] in Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
4487-5 |
|
|
|
|
Both |
|
|
|
0 |
C3 Frg RBC-mCnc |
|
|
|
Y |
|
Beta 1 C-globulin; C3 Frg; Comp; Complmt; Erythrocytes; Frag; Fragments; HEMATOLOGY/CELL COUNTS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Red blood cells; Red blood corpusles |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
44870-4 |
Histoplasma capsulatum Ag |
PrThr |
Urine |
Pt |
Ord |
RIA |
|
ACTIVE |
Histoplasma capsulatum Ag [Presence] in Urine by Radioimmunoassay (RIA) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44870-4 |
|
RIA |
|
|
Both |
|
|
|
0 |
H capsul Ag Ur Ql RIA |
|
|
|
N |
|
Antigen; Antigens; H capsul; H capsulatum; H farciminosum; Histo; Histopl; Histoplasma farciminosum; Histoplasmos; Histoplasmosis; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Radioimmunoassay; Random; Screen; UA; UR; Urn |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44871-2 |
HIV 1 proviral DNA |
PrThr |
Bld |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
HIV 1 proviral DNA [Presence] in Blood by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44871-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HIV 1 pro DNA Bld Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; AIDS; Amplif; Amplification; Amplified; Blood; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HIV type 1; HIV type I; HIV1; HIV1 proviral DNA; Human immunodeficiency virus; i; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to Threshold to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44872-0 |
HIV 1 p24 Ag |
PrThr |
Ser/Plas^Donor |
Pt |
Ord |
IA |
|
ACTIVE |
HIV 1 p24 Ag [Presence] in Serum or Plasma from Donor by Immunoassay |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44872-0 |
|
IA |
|
|
Both |
|
|
|
0 |
HIV1 p24 Ag SerPl Donr Ql IA |
|
|
|
N |
|
AIDS; Antigen; Antigens; Donr; EIA; ELFA; ELISA; Enzyme immunoassay; HIV type 1; HIV type I; HIV1; HIV1 p24; Human immunodeficiency virus; i; IAA; ID; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
44873-8 |
HIV 1+2 Ab |
PrThr |
Ser |
Pt |
Ord |
IB |
|
ACTIVE |
HIV 1+2 Ab [Presence] in Serum by Immunoblot |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44873-8 |
|
IB |
|
|
Observation |
|
|
|
0 |
HIV1+2 Ab Ser Ql IB |
|
|
|
N |
|
ABS; Aby; AIDS; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Blt; HIV 1 & 2; HIV 1 and 2 Ab; HIV type 1; HIV type I; HIV1; HIV1+2; Human immunodeficiency virus; i; ID; II; Immune blot; Immunobl; Immunoblot; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; RIBA; Screen; Serum; SR; WB; WBLOT; West blot; West blt; Western blot |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44874-6 |
HTLV I+II RNA |
PrThr |
Ser |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
HTLV I+II RNA [Presence] in Serum by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44874-6 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HTLV I+II RNA Ser Ql NAA+probe |
|
|
|
N |
|
2; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; HTLV type 1+2; HTLV type I+II; Human T-cell Leukemia Virus; Human T-cell Lymphotrophic Virus; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; Serum; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.63 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44875-3 |
IgM Ag |
PrThr |
Skin |
Pt |
Ord |
IF |
|
ACTIVE |
IgM Ag [Presence] in Skin by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
44875-3 |
|
IF |
|
|
Both |
|
|
|
0 |
IgM Ag Skin Ql IF |
|
|
|
N |
|
ACIF; Anticomplement Immunofluorescence; Antigen; Antigens; Chemistry; Dermatologic; DFA; Epidermis; FA; Fluorescent antibody; Fluoresent; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Integument; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Skn; Time Resolved Fluorescence; TRF |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44876-1 |
Influenza virus A Ab |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Influenza virus A Ab [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44876-1 |
|
|
|
|
Both |
|
|
|
0 |
FLUAV Ab CSF Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Avian influenza; Bird flu; Cerebral spinal fluid; Cerebrospinal Fl; FLUA; FLUAV; FLUV; Fowl plague; ID; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44877-9 |
Insulin dependent diabetes mellitus |
PrThr |
^Patient |
Pt |
Ord |
|
|
ACTIVE |
Insulin dependent diabetes mellitus [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MISC |
|
44877-9 |
|
|
|
|
Observation |
|
|
|
0 |
IDDM Patient Ql |
|
|
|
N |
|
DM; HUM; Humulin; IDDM; IH7; Insul; Lente; MISC; NPH; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Semilente; Sliding; Ultralente |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
44878-7 |
Staphylococcus aureus enterotoxin A sea gene |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Staphylococcus aureus enterotoxin A sea gene [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
See comments for sample results |
|
|
|
|
|
MICRO |
|
44878-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
S aureus Etx A gene Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; Etx; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; m80; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; o71; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; S aureus; S aureus Etx; S aureus Etx A; S aureus Etx A gene; Screen; SDA; sea; Spec; St a SEA; Staph; Staphylococcal enterotoxin; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; Removed parentheses around "sea" gene in Component based on the current LOINC model. |
0 |
44879-5 |
Staphylococcus aureus enterotoxin E see gene |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Staphylococcus aureus enterotoxin E see gene [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44879-5 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
S aureus Etx E gene Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; Etx; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; o71; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Rm225; S aureus; S aureus Etx; S aureus Etx E; S aureus Etx E gene; Screen; SDA; see; Spec; Staph; Staphylococcal enterotoxin; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; Removed parentheses around "see" gene in Component based on the current LOINC model. |
0 |
4488-3 |
Complement C3a |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Complement C3a [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
HEM/BC |
|
4488-3 |
|
|
|
|
Both |
|
|
|
0 |
C3a SerPl-mCnc |
|
|
|
Y |
|
Comp; Complmt; HEMATOLOGY/CELL COUNTS; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
44880-3 |
Staphylococcus aureus enterotoxin B seb gene |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Staphylococcus aureus enterotoxin B seb gene [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44880-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
S aureus Etx B gene Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; Etx; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; m81; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; o71; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; S aureus; S aureus Etx; S aureus Etx B; S aureus Etx B gene; Screen; SDA; seb; Spec; St a SEB; Staph; Staphylococcal enterotoxin; Strand Displacement Amplification; TMA; To be specified in another part of the message; Toxic shock syndrome enterotoxin b; Transcription mediated amplification; Unspecified |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; Removed parentheses around "seb" gene in Component based on the current LOINC model. |
0 |
44881-1 |
Staphylococcus aureus toxic shock syndrome toxin gene |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Staphylococcus aureus toxic shock syndrome toxin gene [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
44881-1 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
S aureus TSST gene Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; o71; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; S aureus; S aureus TSST gene; Screen; SDA; Spec; Staph; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |